WilmerHale Advises Verve Therapeutics in $306M IPO

WilmerHale Advises Verve Therapeutics in $306M IPO

Firm News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
A deep and diverse practice focused on maximizing tax efficiencies and minimizing tax risks for clients nationally and internationally.
Critical industry insight and formidable strength across key practices.

On June 21, 2021, Verve Therapeutics (Nasdaq: VERV), a biotech company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced the closing of its initial public offering of 16,141,157 shares of its common stock, which includes 2,105,368 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $19.00 per share. Including the option exercise, the aggregate gross proceeds to Verve Therapeutics from the offering were approximately $306.7 million, before deducting the underwriting discounts and commissions and offering expenses. J.P. Morgan, Jefferies, Guggenheim Securities and William Blair acted as joint book-running managers for the offering.

The WilmerHale team advising Verve Therapeutics was led by Lia Der Marderosian, Craig Hilts and Ciara Baker, and included Timothy Kulis, Erin Garrity, Chris Shin and Alex Bloom.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel